Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Abdel-Wahab, Omar  [Clear All Filters]
2024
Benbarche S, Pineda JMario Bell, Galvis LBaquero, Biswas J, Liu B, Wang E, Zhang Q, Hogg SJ, Lyttle K, Dahi A, et al. GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies. Mol Cell. 2024.
Izzo F, Myers RM, Ganesan S, Mekerishvili L, Kottapalli S, Prieto T, Eton EO, Botella T, Dunbar AJ, Bowman RL, et al. Mapping genotypes to chromatin accessibility profiles in single cells. Nature. 2024.
2023
Stahl M, Bewersdorf JPhilipp, Xie Z, Porta MGiovanni D, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, et al. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023:101128.
Bewersdorf JPhilipp, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, et al. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1 International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev. 2023:101072.
Ptashkin RN, Ewalt MD, Jayakumaran G, Kiecka I, Bowman AS, Yao JJ, Casanova J, Lin Y-TDavid, Petrova-Drus K, Mohanty AS, et al. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nat Commun. 2023;14(1):6895.
Cortés-López M, Chamely P, Hawkins AG, Stanley RF, Swett AD, Ganesan S, Mouhieddine TH, Dai X, Kluegel L, Chen C, et al. Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths. Cell Stem Cell. 2023.
Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, Rameau P, Catelain C, Alfaro A, Edmond V, et al. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia. 2023.
Knorr K, Rahman J, Erickson C, Wang E, Monetti M, Li Z, Ortiz-Pacheco J, Jones A, Lu SX, Stanley RF, et al. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nat Cancer. 2023.
Ge G, Zhang P, Sui P, Chen S, Yang H, Guo Y, Rubalcava IP, Noor A, Delma CR, Agosto-Peña J, et al. Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models. J Clin Invest. 2023.
2022
Marabti EEl, Abdel-Wahab O. Enhancing CD19 chimeric antigen receptor T cells through memory enriched T cells. Clin Cancer Res. 2022.
2020
Viaud M, Abdel-Wahab O, Gall J, Ivanov S, Guinamard R, Sore S, Merlin J, Ayrault M, Guilbaud E, Jacquel A, et al. ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. Cell Rep. 2020;30(10):3397-3410.e5.
Izzo F, Lee SC, Poran A, Chaligne R, Gaiti F, Gross B, Murali RR, Deochand SD, Ang C, Jones PWyndham, et al. DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nat Genet. 2020.
2018
Lee SChun-Wei, North K, Kim E, Jang E, Obeng E, Lu SX, Liu B, Inoue D, Yoshimi A, Ki M, et al. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell. 2018;34(2):225-241.e8.
2015
Fong CYew, Gilan O, Lam EYN, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015.
Zhang L, Tung N-T, Su H, Wang R, Lu Y, Tang H, Aoyagi S, Guo A, Khodadadi-Jamayran A, Zhou D, et al. Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing. Elife. 2015;4.
2014
Chung YRock, Kim E, Abdel-Wahab O. Femoral Bone Marrow Aspiration in Live Mice. J Vis Exp. 2014;(89).
Lee SChun-Wei, Abdel-Wahab O. The mutational landscape of paroxysmal nocturnal hemoglobinuria revealed: new insights into clonal dominance. J Clin Invest. 2014:1-4.
2013
Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YRock, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave LM, et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med. 2013.